ArticleGenome medicine2013
Characterizing biobank organizations in the U.S.: results from a national survey.
Article in Genome medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Strengthening the reporting of observational studies in epidemiology using Mendelian randomization (STROBE-MR): a Korean translation of explanation and elaboration.Ewha medical journal · 2025Guideline
- Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways.Clinical pharmacology and therapeutics · 2026Review
- Current situation and future prospect of biobank.CytoJournal · 2026Review
- Reduced order computational fluid dynamic simulations in the thoracic aorta are associated with disease recorded in a medical biobank.Scientific reports · 2025Article
- Development of a big data platform for collecting and utilizing clinical information from the Korea Biobank Network.BMC medical informatics and decision making · 2025Article
- Re-consent practices in biobanks in Japan: current status and stakeholder perspectives.Journal of community genetics · 2025Article
- Incorporating biobanking into the future of healthcare: exploring patient and healthcare worker perspectives at a Canadian tertiary academic hospital.European journal of human genetics : EJHG · 2025Article
- Building a Decentralized Biobanking App for Research Transparency and Patient Engagement: Participatory Design Study.JMIR human factors · 2025Article
- How to communicate and what to disclose to participants in a recall-by-genotype research approach: a multistep empirical study.Journal of community genetics · 2024Article
- Efficient Use of Biological Data in the Web 3.0 Era by Applying Nonfungible Token Technology.Journal of medical Internet research · 2024Article
- Strategies for Implementing Machine Learning Algorithms in the Clinical Practice of Radiology.Radiology · 2024Review
- Stakeholder engagement to ensure the sustainability of biobanks: a survey of potential users of biobank services.European journal of human genetics : EJHG · 2022Article
- Positive association between research competitiveness of Chinese academic hospitals and the scale of their biobanks: A national survey.Clinical and translational science · 2022Article
- The Evolution of a Large Biobank at Mass General Brigham.Journal of personalized medicine · 2022Article
- Novel Analysis Methods to Mine Immune-Mediated Phenotypes and Find Genetic Variation Within the Electronic Health Record (Roadmap for Phenotype to Genotype: Immunogenomics).The journal of allergy and clinical immunology. In practice · 2022Review
- The Availability of Human Biospecimens to Support Biomarker Research.Biomarker insights · 2022Review
- Paediatric biobanking for health: The ethical, legal, and societal landscape.Frontiers in public health · 2022Review
- Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration.BMJ (Clinical research ed.) · 2021Article
- Analysis of Biospecimen Demand and Utilization of Samples from the National Amyotrophic Lateral Sclerosis Biorepository.Biopreservation and biobanking · 2021Article
- A high-throughput phenotyping algorithm is portable from adult to pediatric populations.Journal of the American Medical Informatics Association : JAMIA · 2021Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective translational biomedical research hinges on the operation of 'biobanks,' repositories that assemble, store, and manage collections of human specimens and related data. Some are established intentionally to address particular research needs; many, however, have arisen opportunistically, in a variety of settings and with a variety of expectations regarding their functions and longevity. Despite their rising prominence, little is known about how biobanks are organized and function beyond simple classification systems (government, academia, industry).
methodsIn 2012, we conducted the first national survey of biobanks in the U.S., collecting information on their origins, specimen collections, organizational structures, and market contexts and sustainability. From a list of 636 biobanks assembled through a multi-faceted search strategy, representatives from 456 U.S. biobanks were successfully recruited for a 30-minute online survey (72% response rate). Both closed and open-ended responses were analyzed using descriptive statistics.
resultsWhile nearly two-thirds of biobanks were established within the last decade, 17% have been in existence for over 20 years. Fifty-three percent listed research on a particular disease as the most important reason for establishment; 29% listed research generally. Other reasons included response to a grant or gift, and intent to centralize, integrate, or harmonize existing research structures. Biobank collections are extraordinarily diverse in number and types of specimens and in sources (often multiple) from which they are obtained, including from individuals, clinics or hospitals, public health programs, and research studies. Forty-four percent of biobanks store pediatric specimens, and 36% include postmortem specimens. Most biobanks are affiliated in one or multiple ways with other entities: 88% are part of at least one or more larger organizations (67% of these are academic, 23% hospitals, 13% research institutes). The majority of biobanks seem to fill a particular 'niche' within a larger organization or research area; a minority are concerned about competition for services, although many are worried about underutilization of specimens and long-term funding.
conclusionsEffective utilization of biobank collections and effective policies to govern their use will require understanding of the immense diversity found in organizational features, including the very different history and primary goals that many biobanks have.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.